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Objectives. Development of a simple mutation directed method in order to allow lowering the cost of mutation testing using an
easily obtainable biological material. Assessment of the feasibility of such method was tested using a GC-rich amplicon. Design
and Methods. A method of denaturing high-performance liquid chromatography (dHPLC) was improved and implemented as a
technique for the detection of variants in exon 9 of the IDUA gene.The optimized method was tested in 500 genomic DNA samples
obtained from dried blood spots (DBS). Results. With this dHPLC approach it was possible to detect different variants, including
the common p.Trp402Ter mutation in the IDUA gene. The high GC content did not interfere with the resolution and reliability of
this technique, and discrimination of G-C transversions was also achieved. Conclusion. This PCR-based dHPLC method is proved
to be a rapid, a sensitive, and an excellent option for screening numerous samples obtained from DBS. Furthermore, it resulted
in the consistent detection of clearly distinguishable profiles of the common p.Trp402Ter IDUA mutation with an advantageous
balance of cost and technical requirements.
1. Introduction
Mucopolysaccharidosis type I (MPS I) is a rare autoso-
mal recessive disorder resulting from deficiency of the
enzyme 𝛼-L-iduronidase (IDUA, E.C. 3.2.1.76) and leads
to the intralysosomal accumulation of undegraded gly-
cosaminoglycans [1]. The gene encoding 𝛼-L-iduronidase
(IDUA, OMIMno. 252800) is located on chromosome
4p16.3 and contains 14 exons [2–4]. The most common
IDUA mutation identified in MPS I patients is p.Trp402Ter
(NG 008103.1: g.20751G>A, NM 000203.3: c.1205G>A, and
NP 000194.2: p.Trp402Ter) which represents at least 45% of
the causal alleles in Northwestern Europe, North America,
Australia, Portugal, and Spain, while in Russia, Italy, and
Brazil its frequency has been estimated to be 4%, 11%, and
37%, respectively [5, 6].
Since p.Trp402Ter is the single most common causal
mutation inMPS IH (OMIM no. 607014) patients ofWestern
European origin and accounts for 60% of the alleles in
unrelated Portuguese patients [7], we wanted to develop a
rapid and reliable method for the convenient detection of this
IDUAmutation (OMIMno. 252800.0001).
Denaturing high-performance liquid chromatography
(dHPLC) was successfully applied to the screening of muta-
tions involved in various diseases [8], including MPS I [9].
We optimized an efficient dHPLC method and validated its
application to mutation screening using DBS as source of
biological material. This semiautomated technique results
in clear profiles and facilitates the accurate detection of
the p.Trp402Ter mutation in the IDUA gene, allowing the
screening of a large number of samples. Conventional meth-
ods for large-scale detection of mutations, such as SSCP,
CSGE, RFLP, and sequencing, are expensive, are technically
demanding, are time consuming, and sometimes have limited
resolution. The application of dHPLC allows the discrimina-
tion of mutations at a cost that is fourfold lower than dye-
terminator sequencing. The presently described approach
is a cost effective, sensitive, and reproducible method for
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Table 1: PCR amplification conditions.
Exon 9 Amplicon size (bp) GC content (%) Primers (5󸀠 → 3󸀠) PCR program




Nested PCR 208 77 F-GGCGGCTGGGCAACGACC 72
∘C/1min
R-GTGGGCGCGGGTGTCGTC 72∘C/10min
PCR reactions were performed using PCRMasterMix (Promega) without any additives, 20 pmol of forward primer and 20 pmol of reverse primer; in the first
PCR, 4𝜇L (4-5 ng) of DNAwas used in a 10𝜇L final volume; in the nested PCR, 1𝜇L of a 1/10 dilution of the first PCR product was used in a 20𝜇L final volume.
screening large numbers of samples, even from distant loca-
tions, with minimal technical requirements.
2. Materials and Methods
2.1. Biological Materials. A total of 500 samples from
anonymized individuals born in Portugal were randomly
selected. These 500 samples consisted of surplus remainder
samples of dried blood spots (Guthrie cards, DBS) from the
National Program of Neonatal Screening (Instituto Nacional
de Sau´de Dr. Ricardo Jorge, Centro de Gene´tica Me´dica Dr.
Jacinto Magalha˜es). Appropriate approval for investigational
use was obtained in accordance with national and institu-
tional ethical regulations. Control heterozygous (GM00799)
and homozygous (GM00798) human skin fibroblast cell lines
with p.Trp402Ter mutation were obtained from the Coriell
Institute for Medical Research. Genomic DNAwas automati-
cally extracted using a Maxwell 16 System (Promega). DNA
from 3 punches (2mm ø) yielded approximately 250 ng of
DNA with a purity of 1.8 (A260/A280), and 5 ng of DNA
was used as template in the PCR reaction. Differences in
sample quality from gDNA extracted from different sources
(fibroblast cell lines andDBS)wereminimized by the dilution
of the template used for obtaining the final amplicon for
dHPLC analysis.
2.2. PCR Amplification. PCR primers were based on those
proposed by Kasper and collaborators [9] withmodifications,
namely, removal of (GC) clamps and amplification of a
smaller fragment for dHPLC analysis. Optimization of the
PCR reaction was performed by varying PCR conditions
including Taq mixes, cycle temperatures/times, and template
concentrations. Table 1 shows the final PCR conditions. PCR
with 5 ng of template DNA resulted in clear and abundant
amplicons that did not require any purification procedure.
Prior to the dHPLC optimization, the IDUA gene of control
samples was sequenced in order to ensure its integrity.
2.3. dHPLC Conditions. Denaturing high-performance liq-
uid chromatography (dHPLC) analysis was performed using
an automatedWAVENucleic Acid Fragment Analysis System
and respective Wavemaker 3.4 software (Transgenomic).
Melt Program from Stanford Genome Technology Center
(http://insertion.stanford.edu/melt) was used for the opti-
mization of dHPLC conditions.
Prior to dHPLC analysis, PCR products were heated to
96∘C for 3min and slowly cooled to 65∘C using a ramping
of 0.1∘C for each 6 sec (62 cycles). Five𝜇L of the cooled PCR
product was applied onto a preheated C18-reversed phase
column (DNASep column, Transgenomic). DNA was eluted
at a flow rate of 0.9mL/min within a linear acetonitrile
gradient consisting of Buffer A (0.1M triethylammonium
acetate (TEAA)) and Buffer B (0.1MTEAA, 25% acetonitrile)
and detected spectrophotometrically by UV absorption.
The optimal percentage of Buffer B was 52%, run time
and column temperature were 8min and 68.5∘C, respectively.
After each run, regeneration of the column was achieved by
washing with 100% Solution D (Transgenomic) for 0.5min
followed by an equilibration time of 2min. To test the dHPLC
capacity for detecting p.Trp402Ter, DNA from wild type and
homozygote were mixed in different proportions. Samples
with abnormal heteroduplex patterns, as well as randomly
selected sampleswith normal profiles, were amplified de novo
and subjected to direct automated sequencing.
3. Results
The optimal PCR conditions were as described in the
methods section. Optimization of dHPLC conditions and
subsequent dHPLC analysis of PCR products was carried
out using samples with and without the p.Trp402Ter IDUA
mutation in order to validate the technique. A total of 500
DNA samples, plus previously characterized controls, were
then amplified and analyzed by the dHPLC technique. As
seen in Figure 1, a variant dHPLC profile was detected in the
case of a p.Trp402Ter heterozygous carrier, and four addi-
tional dHPLC variant profiles were obtained corresponding
to homozygosity or heterozygosity for the SNP p.Thr410=
(NG 008103.1: g.20776C>G, NM 000203.3: c.1230C>G,
and rs115790973) and homozygosity or heterozygosity
for the SNP p.Gly409Arg (NG 008103.1: g.20771G>C,
NM 000203.3: c.1225G>C, and rs11934801). Each of the
five different dHPLC profiles was distinguishable and
characterization was achieved by DNA sequencing.
The allele frequency of SNP p.Gly409Arg was 4%,
whereas SNP p.Thr410= had an allele frequency of 17% (for
the allelic form g.20776G), similar to the one reported in
databases, demonstrating the consistent detection of alter-
ations and the reproducibility of the assay. The dependable
detection of the p.Trp402Ter mutation in heterozygous con-
trol samples showed the reliability of the assay, which was
further reinforced by the finding of a heterozygous sample
among the 500 randomly selected samples tested.
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Figure 1: Different dHPLC profiles of the exon 9 of IDUA gene. Presence of heteroduplexes when the absorbance was measured against time.
Differences were observed between dHPLC profiles of wild-type amplicons and amplicons carrying the p.Trp402Ter mutation or the SNPs
p.Thr410= or p.Gly409Arg. As shown, retention times were 4 to 6 minutes. Profiles were normalized according to their height, elution time,
and endpoints.
The use of dried blood spots as source of DNA for dHPLC
analysis was validated by the regularity of the results.
4. Discussion
The existence of multiple nucleotide variations, along with
high GC content and with mutations leading to decreased
levels of mRNA, interferes with the efficiency of mutation
detection techniques, namely, with SSCP, allele discrimina-
tion, and cDNA sequencing. With dHPLC’s high level of
detection, reproducibility, sensitivity, and resolution, even in
GC-rich regions, we were able to discriminate between nor-
mal, mutated, and polymorphic alleles. The polymorphisms
detected in this study were not detected in combination with
the causal mutation p.Trp402Ter. As previously described by
other groups, DBS represent an extremely convenient source
of biological material [10] for mutational and biochemical
screenings. This point becomes particularly important since,
unlike with enzyme assays in which differences were found
between DBS and leukocyte activities [11], in the case of DNA
no difference was found in the results obtained from different
sources of biological materials. The successful use of dried
blood spots (DBS) validates the use of these samples as a
reliable source of biological material for the application of
the described laboratorial approach.Therefore the use of DBS
is not only practical and economical but is also convenient
for the large screenings or to the study of samples from
distant locations. Since themolecular lesion tested is themost
common causal mutation of MPS IH in Western European
populations, this could be a preferable method for initial
screening in populations with that particular ancestry.
According to different reports the use of dHPLC as a
mutation screening method is particularly advantageous, not
only because of its simplicity and sensitivity [12] but also
due to its cost, which has been estimated to be about 80%
lower than that direct sequencing [13, 14]. Although the
cost might vary depending on the country, in our case of
it was estimated to be 3,50 euro/sample (as opposed to 14
euro per sample sequencing). Considering the use of other
alternative techniques, such as SSCP or allelic discrimination,
this optimized method showed a clear advantage by allowing
the efficient identification of alterations in a GC-rich region
while requiring very low template concentrations.
In conclusion, with this work, we improved and devel-
oped a dHPLC screening method aiming at the detection of
variations in a region of the IDUA gene with a GC content
of 77%. This dHPLC technique was found to be a very useful
screening tool since it is a sensitive, automatable, economical,
and highly robust method. The combination of dHPLC with
the usewithDBS samplesmakes this approachmost adequate
for the screening of numerous samples.
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